drugset / Trial / NCT04022213
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Phase 2
Active not recruiting
31 enrolled
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Timeline
- Start
- 2019-07-15
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 131I-omburtamab | Monoclonal antibody | 80 unknown | Other |